HJ Science Co., Ltd. (SEHK: 6132)
Health Care · Biotechnology · CN
HK$32.44
-2.99% today · -8.0% 1Y
HJ Science Co., Ltd. (SEHK: 6132) operates in the Biotechnology industry within the Health Care sector. The company is valued at $304.32M and employs 113 people.
Over the last twelve months the share price has lost 8.0%, trading between 25.88 and 82.00.
Tweenvest scores HJ Science Co., Ltd. across four factors: quality 53/100, value 67/100. Its strongest factor is value.
6132 price history
Key figures
- Market cap
- $304.32M
- Revenue (TTM)
- $2.08M
- P/E
- -10.82
- EPS
- -2.54
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$82.00
- 52-week low
- HK$25.88
- Avg volume (3M)
- —
- Shares outstanding
- 73.60M
- Employees
- 113
- Next earnings
- —
About HJ Science Co., Ltd.
HJ Science Co., Ltd. is a clinical stage biotech company, which engages in research and development of small molecule drugs for tumors, autoimmune & metabolic system diseases for clinical treatments. It provides drug design, in vivo and in vitro activity evaluation, drug metabolism, synthesis, quality research, formulation development, and scale-up. Its products include HJ787, HJ178 and HJ891. The company was founded by Ji Jianxin on February 20, 2017 and is headquartered in Chengdu, China.
- ISIN
- CNE100007PD2
- Founded
- 2017
- Listed since
- Jun 23, 2026
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Scribe Therapeutics Inc.NasdaqGM: SCTX | $309.82M | $16.36 | -3.71% |
| Galectin Therapeutics Inc.NasdaqCM: GALT | $307.59M | $3.05 | -2.87% |
| Vector Science and Therapeutics Corp.TSXV: PAIN | $307.08M | CA$2.80 | +16.67% |
| Jiangsu Recbio Technology Co., Ltd.SEHK: 2179 | $306.59M | HK$3.90 | 0.00% |
| Kyverna Therapeutics, Inc.NasdaqGS: KYTX | $300.94M | $4.76 | -5.74% |
| Vicore Pharma Holding AB (publ)OM: VICO | $299.86M | Skr10.72 | -2.37% |
| Century Therapeutics, Inc.NasdaqCM: IPSC | $299.64M | $1.65 | +1.23% |
| Evommune, Inc.NYSE: EVMN | $299.37M | $7.24 | +5.23% |